COMMUNIQUÉS West-GlobeNewswire

Theratechnologies annonce le dépôt des documents relatifs à l’assemblée extraordinaire et l’obtention d’une ordonnance provisoire concernant son acquisition par CB Biotechnology, un membre du même groupe que Future Pak
18/08/2025
Les actionnaires pourraient recevoir une prime en espèces considérable et attrayante puisque le prix d’achat de 3,01 $ US, assorti d’un droit conditionnel à la valeur représentant des paiements supplémentaires totaux [...]
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
18/08/2025
Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 100% CR/CRh at 80 mg [...]
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
18/08/2025
Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home (Outpatient) setting sNDA submission on track for Q1 2026 NEW HAVEN, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel [...]
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
18/08/2025
Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation [...]
SRx Health Solutions Signed a Letter of Intent to Acquire the Assets of Royal Uranium
18/08/2025
TAMPA, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (“SRx Health” or the “Company”), a leading global health and wellness company, today announced that is has signed a non- [...]
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
18/08/2025
Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID ® Separate single-arm [...]
Virbac:: Paul Martingell's compensation terms
18/08/2025
The board of directors of Virbac specifies Paul Martingell's compensation terms as chief executive officer. The board of directors, acting upon the recommendation of the appointments and compensation committee, has [...]
VIRBAC: Informations sur les conditions de rémunération de Paul Martingell
18/08/2025
Le conseil d’administration de Virbac précise les conditions de rémunération de Paul Matingell en qualité de directeur général. Le conseil d’administration a arrêté, sur recommandation du comité des nominations et des [...]
Clarity Health Care is Coming to Malvern
18/08/2025
Unique mental health clinic to provide integrated care to Melbourne’s inner south-east MELBOURNE, Australia, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Clarity Health Care, a leading provider of multidisciplinary mental health [...]
New Novartis ESC data highlights strength of cardiovascular portfolio
18/08/2025
Two VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol lowering monotherapy Lp(a)FRONTIERS APHERESIS study will assess effect of pelacarsen on reducing need for lipoprotein [...]
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
18/08/2025
Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine [...]
Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé au Canada pour les personnes âgées de 12 ans et plus
18/08/2025
Saint-Herblain (France), le 18 août 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que Santé Canada a accordé une autorisation de mise sur le marché [...]
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
18/08/2025
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and [...]

Pages